News

Video

Phase 1b Study of Azacitidine, Venetoclax and Revumenib in Newly Diagnosed Older Adults with NPM1 Mutated or KMT2A Rearranged AML: Interim Results of Dose Escalation from the Beat AML Consortium

Author(s):

Joshua F. Zeidner, MD

A Phase 1b study (NCT03013998) to determine the safety and recommended dose of Revumenib combined with Aza/Ven in patients with newly diagnosed AML ≥ 60 years old with NPM1mut or KMT2Ar and who are not candidates or do not wish to pursue intensive induction therapy.

Related Videos
Grzegorz S. Nowakowski, MD
John Seymour, MBBS, FRACP, PhD
Reid Merryman, MD
Partow Kebriaei, MD
Jean L. Koff, MD, MS
Sonali M. Smith, MD
Naval G. Daver, MD,
Andrew Hantel, MD
Naval G. Daver, MD
A panel of 3 experts on ALL
Related Content
Michael Marrone, PhD, MPH
September 10th 2024

Real-World Data for Pacritinib Show Improvement in Thrombocytopenia, Anemia in Myelofibrosis

OncLive On Air
March 18th 2024

Revisit the OncLive On Air Episodes From February 2024

Jason R. Westin, MD, of The University of Texas MD Anderson Cancer Center
September 7th 2024

Frontline Golcadomide/R-CHOP Combo Elicits Antitumor Activity in Aggressive B-Cell Lymphoma

Matthew Lunning, DO, FACP
November 30th 2023

Lunning and Jacobson Dissect the Role of CAR T-Cell Therapy in Follicular Lymphoma

William G. Wierda, MD, PhD
September 6th 2024

Liso-Cel Elicits Consistent Responses in R/R CLL/SLL, Irrespective of High-Risk Features

Stefan K. Barta, MD, MS
September 6th 2024

Valemetostat Demonstrates Clinically Meaningful Efficacy in R/R PTCL